At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Zilebesiran (drug), Placebo (drug)
- How long the study runs
- Study runs about 60 months (dates as stated)
- About the drug or intervention
- Zilebesiran — drug: Zilebesiran will be administered SC · Placebo — drug: Placebo will be administered SC
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 11,000
- Started
- 2025-09-22
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for high risk cardiovascular disease
- • Phase3 - 11,000 participants
- • The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with high risk cardiovascular disease
Where?
- • Ashburton - Clinical Trial Site
- • Belfast - Clinical Trial Site
- • Bellshill - Clinical Trial Site
- • Birmingham - Clinical Trial Site
- • +45 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Is 18 years or older for patients with established cardiovascular disease (CVD)
- ✓Is 55 years or older for patients with high risk for CVD
- ✓Has established CVD (defined as coronary, cerebrovascular, or peripheral artery disease) or high risk for CVD
- ✓Has treated hypertension on stable therapy with at least 2 the usual treatment antihypertensive medications, one of...
Who cannot take part
- ✗Has known history of secondary hypertension
- ✗Has causing symptoms orthostatic hypotension
- ✗Has alanine aminotransferase (liver enzymes) or aspartate aminotransferase (liver enzymes) \>3×upper limit of normal (ULN)
- ✗Has total serum liver blood test \>1.5×ULN
- ✗Has international normalized ratio (INR) \>1.5
See the full criteria
Where Is This Study? (49 UK sites)
Clinical Trial Site
Ashburton TQ13 7AP, United Kingdom
Clinical Trial Site
Belfast BT2 8BG, United Kingdom
Clinical Trial Site
Bellshill ML4 3NJ, United Kingdom
Clinical Trial Site
Birmingham B15 2SQ, United Kingdom
Clinical Trial Site
Birmingham B21 9RY, United Kingdom
Clinical Trial Site
Bristol BS2 8HW, United Kingdom
Clinical Trial Site
Bristol BS37 4AX, United Kingdom
Clinical Trial Site
Bury St Edmunds IP33 2QZ, United Kingdom
Clinical Trial Site
Cambridge CB2 0QQ, United Kingdom
Clinical Trial Site
Cardiff CF15 9SS, United Kingdom
Clinical Trial Site
Cardiff CF5 4AD, United Kingdom
Clinical Trial Site
Chichester PO19 6SE, United Kingdom
Clinical Trial Site
Corby NN17 2UR, United Kingdom
Clinical Trial Site
Darlington DL3 6HX, United Kingdom
Clinical Trial Site
Dorchester DT1 2JY, United Kingdom
Clinical Trial Site
Ely CB7 5JD, United Kingdom
Clinical Trial Site
Fowey PL23 1DT, United Kingdom
Clinical Trial Site
Glasgow G20 7BE, United Kingdom
Clinical Trial Site
Heston TW5 9ER, United Kingdom
Clinical Trial Site
Honiton EX14 2NY, United Kingdom
Clinical Trial Site
Ilford IG1 4HP, United Kingdom
Clinical Trial Site
Isleworth TW7 6AF, United Kingdom
Clinical Trial Site
Leeds LS26 9AA, United Kingdom
Clinical Trial Site
Liskeard PL14 3XA, United Kingdom
Clinical Trial Site
Liverpool L24 7RB, United Kingdom
Clinical Trial Site
Liverpool L9 7AL, United Kingdom
Clinical Trial Site
London EC1A 7BE, United Kingdom
Clinical Trial Site
London SE6 4LF, United Kingdom
Clinical Trial Site
Luton LU4 0DZ, United Kingdom
Clinical Trial Site
Manchester M13 9WL, United Kingdom
Clinical Trial Site
Manchester M27 8FF, United Kingdom
Clinical Trial Site
Metropolitan Borough of Wirral CH62 6EE, United Kingdom
Clinical Trial Site
Middlesbrough TS5 6HA, United Kingdom
Clinical Trial Site
Milton Keynes MK15 0DU, United Kingdom
Clinical Trial Site
Newquay TR7 1RU, United Kingdom
Clinical Trial Site
Northallerton DL7 8AW, United Kingdom
Clinical Trial Site
Penzance TR18 3DX, United Kingdom
Clinical Trial Site
Plymouth PL5 3JB, United Kingdom
Clinical Trial Site
Plympton PL7 1AD, United Kingdom
Clinical Trial Site
Poole BH16 5PW, United Kingdom
Clinical Trial Site
Redhill RH1 5RH, United Kingdom
Clinical Trial Site
Sale M33 4BR, United Kingdom
Clinical Trial Site
Swansea SA2 8QA, United Kingdom
Clinical Trial Site
Swindon SN3 6BB, United Kingdom
Clinical Trial Site
Teeside TS19 8PE, United Kingdom
Clinical Trial Site
Thetford IP24 1JD, United Kingdom
Clinical Trial Site
Torpoint PL11 2TB, United Kingdom
Clinical Trial Site
Wolverhampton WV9 5HB, United Kingdom
Clinical Trial Site
York YO24 2RQ, United Kingdom
How to Get in Touch
Clinical Trial Information Line
Sponsor contactCONTACT
Clinical Trial Information Line
Sponsor contactCONTACT